Document is current
Any future updates will be listed below
-
Authors
Krenn, Katharina
Kraft, Felix https://orcid.org/0000-0002-6297-9256
Mandroiu, Luana
Tretter, Verena
Reindl-Schwaighofer, Roman
Clement, Theresa
Domenig, Oliver
Vossen, Matthias G.
Riemann, Gregor
Poglitsch, Marko
Ullrich, Roman
-
Funding
Funding for this research was provided by:
Medical-scientific fund of the mayor of the capital Vienna (COVID 039)
Dept. of Anesthesia and General Intensive Care, Medical University of Vienna
Apeptico GmbH
- License Information
-
More Information
Article History
Received: 30 October 2023
Accepted: 6 January 2025
First Online: 16 January 2025
Declarations
:
: The study protocol “Exploratory study of the angiotensin metabolite profile in blood as marker for prognosis in COVID-19” was reviewed and approved by the ethics committee of the Medial University of Vienna (EK Nr. 1328/2020 on April 11th, 2020). Informed consent was obtained from all study participants according to the Austrian legislation regulating the consent of conscious and nonconscious patients participating in clinical trials.
: Not applicable.
: KK reports travel expenses from Biotest GmbH and grants from Apeptico GmbH, Biotest GmbH, Alterras Therapeutics GmbH and Bayer AG. OD is a shareholder and employee of Attoquant Diagnostics GmbH. MP is founder, shareholder and former employee of Attoquant Diagnostics GmbH. RU reports travel expenses and honoraria from Biotest GmbH, grants from CCORE, a patent (EP 151897774, minimally invasive liquid lung), and holds equity in CCORE Technology, a medical device company that develops minimally invasive blood purification devices. The other coauthors have no conflicts of interest to declare.
